{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-120282","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.281966+00:00","generated_at":"2026-05-30T06:11:05.251145+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025","bullets":["Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.","First participant dosing anticipated in Q1 2025; interim readout expected H2 2025; study completion in 2026.","Formed Clinical Advisory Board of six lung and liver experts to guide development strategy.","KRRO-110 is first RNA editing oligonucleotide from Korro's OPERA platform, targeting SERPINA1 RNA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-120282","json":"https://secwatch.observer/filing/0000950170-24-120282.json","markdown":"https://secwatch.observer/filing/0000950170-24-120282.md","text":"https://secwatch.observer/filing/0000950170-24-120282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/0000950170-24-120282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024120282/krro-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:11:05.251145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}